Project Grant R01AI203549
Award Date 8/4/26
Completion Date 7/31/31
Dollars Obligated $673K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, San Francisco $772,342 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish the relationship between long-acting antiretroviral therapy drug concentrations and virologic outcomes in real-world clinical settings. The project, titled "Strategies to Predict Success on Long-Acting Therapy in Real-World Settings for HIV (SPLASH),"...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $899,741 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a long-acting injectable therapy for hepatitis B virus in individuals co-infected with HIV. The R61 phase focuses on optimizing the lead entecavir prodrug (MCMQ657) to achieve sustained release maintaining therapeutic levels for up to three months. Work includes pre-formulation and formulation...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $783,740 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop pharmacological interventions enhancing chimeric antigen receptor (CAR) cell-based immunotherapy for HIV-1 infection. The research investigates targeted enhancement of engineered cellular anti-HIV immunity using immune modulators. The project builds on prior studies demonstrating...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $874,531 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model dynamic CD8+ T cell–virus interactions in post-treatment control of HIV. The project comprehensively defines mechanistic features of CD8+ T cell responses that most strongly relate to control of HIV after stopping antiretroviral therapy. Research will examine...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 11, 2027. The award funds research into the bifunctional role of interleukin-1B in modulating hepatitis B virus replication and host defense during HIV/HBV coinfection. The research addresses how sustained interleukin-1B exposure—a hallmark of HIV-associated systemic inflammation—may enhance HBV replication through p38...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $3.149 million on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop hematopoietic stem cell-based chimeric antigen receptor therapy targeting HIV infection. The research will engineer autologous hematopoietic stem and progenitor cells with anti-HIV CAR molecules to achieve HIV clearance through sustained cellular immune responses,...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $744,483 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how epigenetic heterogeneity and temporal signaling dynamics in B-cell selection shape antibody repertoires and vaccine responses. The funded research examines B-cell fate decisions during antibody-mediated immunity through two primary aims. Aim 1 investigates how dynamic...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $793,623 on August 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered natural killer cells for HIV reservoir targeting. The project, titled "Engineering NK Cells for Effective HIV Reservoir Targeting (ENHANCE)," aims to create chimeric antigen receptor (CAR)-expressing natural killer cells designed to target and eliminate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $463,615 Project Grant to the Regents of the University of California, San Francisco on August 6, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate virologic failure and drug resistance among people with HIV (PWH) receiving long-acting antiretroviral therapy (LA-ART). The VIOLA study, spanning through July 31, 2027, addresses an emerging clinical...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $765,050 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of HIV-1 latency establishment and reactivation across diverse viral isolates and clades. The research explores how long-terminal repeat (LTR) sequence variability within and across HIV-infected individuals influences proviral expression, latency establishment, and...